Read More

Avalo Therapeutics’ Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.

ABBV

Read More

PENN Entertainment And ESPN Bet Hold Potential Amid Regulatory Hurdles: Analyst

Benchmark analyst Mike Hickey assigns a Hold rating to PENN Entertainment, acknowledging its strategic efforts to expand digitally and enhance land-based operations. With a focus on partnerships and online gaming, PENN aims to tap into the lucrative sports betting market projected to exceed $30 billion by 2028.

PENN

Read More

Stocks Grapple With Geopolitical Pressures, Gold Eyes $2,400, Bitcoin Falls Below $62,000: What’s Driving Markets Tuesday?

Investors remain on edge as geopolitics continue to shape market trends, with Israel mulling a response to Iran while the U.S. and key allies explore further sanctions against Tehran.

BAC

Read More

Goldman Sachs Thinks GE Vernova Is Uniquely Positioned To Electrify And Decarbonize Future

Goldman Sachs analyst Joe Ritchie kicks off coverage on GE Vernova with a Buy rating, projecting a target price of $154. Highlighting GEV's significant global electricity contribution and advanced grid technologies, Ritchie anticipates double-digit profitability for the Power business by 2024.

GEV